Shots:
- Italfarmaco & VeriSIM Life have entered into a strategic collaboration to discover & develop novel histone deacetylase (HDAC)-targeted therapeutic assets for neuromuscular, fibrotic, & rare diseases
- As per the deal, VeriSIM Life will receive technology service fees, development, regulatory, & commercial milestone payments, and royalties on future commercial products, with the total potential value exceeding $100M
- The collaboration will utilize VeriSIM Life’s BIOiSIM and AtlasGEN platforms to discover & optimize novel small molecules against a selected HDAC target, using AI-driven drug discovery to prioritize candidates with the strongest potential for clinical translation
Ref: Businesswire | Image: Italfarmaco & VeriSIM Life | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
